DK4073065T3 - Hidtil ukendte methylquinazolinonderivativer - Google Patents
Hidtil ukendte methylquinazolinonderivativer Download PDFInfo
- Publication number
- DK4073065T3 DK4073065T3 DK20817377.3T DK20817377T DK4073065T3 DK 4073065 T3 DK4073065 T3 DK 4073065T3 DK 20817377 T DK20817377 T DK 20817377T DK 4073065 T3 DK4073065 T3 DK 4073065T3
- Authority
- DK
- Denmark
- Prior art keywords
- methylquinazolinone
- derivatives
- previously unknown
- unknown
- previously
- Prior art date
Links
- RLLNOZZVLWEBBI-UHFFFAOYSA-N 4-methyl-3h-quinazolin-2-one Chemical class C1=CC=CC2=C(C)NC(=O)N=C21 RLLNOZZVLWEBBI-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Combines (AREA)
- Harvester Elements (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19214941 | 2019-12-10 | ||
| PCT/EP2020/084976 WO2021116055A1 (en) | 2019-12-10 | 2020-12-08 | New methylquinazolinone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4073065T3 true DK4073065T3 (da) | 2025-04-22 |
Family
ID=68848113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20817377.3T DK4073065T3 (da) | 2019-12-10 | 2020-12-08 | Hidtil ukendte methylquinazolinonderivativer |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12116349B2 (da) |
| EP (2) | EP4483882A3 (da) |
| JP (2) | JP7108146B2 (da) |
| KR (1) | KR102836833B1 (da) |
| CN (2) | CN114787156B (da) |
| AR (1) | AR122351A1 (da) |
| AU (1) | AU2020403443B2 (da) |
| CL (1) | CL2022001529A1 (da) |
| CO (1) | CO2022008968A2 (da) |
| CR (1) | CR20220251A (da) |
| DK (1) | DK4073065T3 (da) |
| ES (1) | ES3023264T3 (da) |
| FI (1) | FI4073065T3 (da) |
| HR (1) | HRP20250418T1 (da) |
| HU (1) | HUE071148T2 (da) |
| IL (2) | IL292161B2 (da) |
| LT (1) | LT4073065T (da) |
| MA (1) | MA58087B1 (da) |
| MX (1) | MX2022006783A (da) |
| PE (1) | PE20221778A1 (da) |
| PH (1) | PH12022551119A1 (da) |
| PL (1) | PL4073065T3 (da) |
| PT (1) | PT4073065T (da) |
| RS (1) | RS66721B1 (da) |
| SI (1) | SI4073065T1 (da) |
| TW (2) | TWI877268B (da) |
| UA (1) | UA128299C2 (da) |
| WO (1) | WO2021116055A1 (da) |
| ZA (2) | ZA202204675B (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4073065T3 (pl) | 2019-12-10 | 2025-05-19 | F. Hoffmann-La Roche Ag | Nowe pochodne metylochinazolinonu |
| PH12022551118A1 (en) * | 2019-12-10 | 2023-09-18 | Hoffmann La Roche | New braf inhibitors as paradox breakers |
| WO2021250521A1 (en) | 2020-06-09 | 2021-12-16 | Array Biopharma Inc. | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders |
| WO2022261250A1 (en) | 2021-06-08 | 2022-12-15 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| AU2022289684A1 (en) * | 2021-06-09 | 2023-10-05 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
| CN117460726A (zh) * | 2021-06-09 | 2024-01-26 | 豪夫迈·罗氏有限公司 | (3r)-n-[2-氰基-4-氟-3-(3-甲基-4-氧代-喹唑啉-6-基)氧基-苯基]-3-氟-吡咯烷-1-磺酰胺的新颖固体形式 |
| BR112023025916A2 (pt) * | 2021-06-09 | 2024-02-27 | Chugai Pharmaceutical Co Ltd | Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção |
| CN117677398A (zh) | 2021-07-27 | 2024-03-08 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| AU2022383040A1 (en) | 2021-11-04 | 2024-03-07 | F. Hoffmann-La Roche Ag | Novel use of quinazolinone compound for the treatment of cancer |
| TW202409040A (zh) | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| CN120265291A (zh) | 2022-11-18 | 2025-07-04 | 豪夫迈·罗氏有限公司 | 喹唑啉酮化合物的新用途和制剂 |
| CN120359214A (zh) * | 2022-12-15 | 2025-07-22 | 豪夫迈·罗氏有限公司 | 用于癌症治疗的组合疗法 |
| JP2025541317A (ja) * | 2022-12-15 | 2025-12-18 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | キナゾリノン誘導体を調製するための方法 |
| AU2024289011A1 (en) | 2023-07-04 | 2025-12-18 | F. Hoffmann-La Roche Ag | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]- 3-fluoro-pyrrolidine-1-sulfonamide |
| WO2025108405A1 (zh) * | 2023-11-22 | 2025-05-30 | 西藏海思科制药有限公司 | 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途 |
| TW202545530A (zh) * | 2024-01-17 | 2025-12-01 | 大陸商海思科醫藥集團股份有限公司 | 含ｂｒａｆ抑制劑的藥物組合物及其在醫藥上的應用 |
| WO2026037755A1 (en) | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | New methylquinazolinone derivatives |
| WO2026046946A1 (en) | 2024-08-28 | 2026-03-05 | F. Hoffmann-La Roche Ag | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4429085B2 (ja) | 2004-06-08 | 2010-03-10 | 有限会社コンペックス | 茸栽培用殺菌菌床組成物の製造法及び茸栽培法 |
| GB0525069D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| SI2947072T1 (sl) | 2008-03-17 | 2017-03-31 | Ambit Biosciences Corporation | 1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2012118492A1 (en) * | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| AR091876A1 (es) | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| ES2612885T3 (es) | 2012-09-19 | 2017-05-19 | Novartis Ag | Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa |
| EP3004060B1 (en) | 2013-05-30 | 2019-11-27 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| CN107801378A (zh) * | 2015-05-22 | 2018-03-13 | 普莱希科公司 | 用于治疗braf‑v600相关的疾病的plx‑8394或plx‑7904 |
| BR112018007161B1 (pt) | 2015-10-09 | 2024-01-16 | Galapagos Nv | COMPOSTOS PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDA N-SULFONILADA, COMPOSIÇÃO FARMACÊUTICA CONTENDO OS DITOS COMPOSTOS E USOS DOS MESMOS PARA TRATAR FIBROSE CÍSTICA |
| RU2687107C1 (ru) | 2018-06-18 | 2019-05-07 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" | Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид |
| JP7539892B2 (ja) | 2019-01-03 | 2024-08-26 | ジェネンテック， インコーポレイテッド | 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物 |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療ｂｒａｆ相關的疾病和失調症之化合物 |
| PH12022551118A1 (en) * | 2019-12-10 | 2023-09-18 | Hoffmann La Roche | New braf inhibitors as paradox breakers |
| PL4073065T3 (pl) * | 2019-12-10 | 2025-05-19 | F. Hoffmann-La Roche Ag | Nowe pochodne metylochinazolinonu |
| WO2021250521A1 (en) | 2020-06-09 | 2021-12-16 | Array Biopharma Inc. | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders |
| WO2022129259A1 (en) | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | New quinazolinone derivatives |
| EP4263541A1 (en) | 2020-12-18 | 2023-10-25 | F. Hoffmann-La Roche AG | New aryl-pyrido-pyrimidin-one derivatives |
| WO2022261250A1 (en) | 2021-06-08 | 2022-12-15 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| EP4444710A1 (en) | 2021-12-08 | 2024-10-16 | Array BioPharma Inc. | Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide |
-
2020
- 2020-12-08 PL PL20817377.3T patent/PL4073065T3/pl unknown
- 2020-12-08 DK DK20817377.3T patent/DK4073065T3/da active
- 2020-12-08 HR HRP20250418TT patent/HRP20250418T1/hr unknown
- 2020-12-08 LT LTEPPCT/EP2020/084976T patent/LT4073065T/lt unknown
- 2020-12-08 PH PH1/2022/551119A patent/PH12022551119A1/en unknown
- 2020-12-08 MX MX2022006783A patent/MX2022006783A/es unknown
- 2020-12-08 JP JP2021566023A patent/JP7108146B2/ja active Active
- 2020-12-08 WO PCT/EP2020/084976 patent/WO2021116055A1/en not_active Ceased
- 2020-12-08 PE PE2022000853A patent/PE20221778A1/es unknown
- 2020-12-08 AU AU2020403443A patent/AU2020403443B2/en active Active
- 2020-12-08 RS RS20250354A patent/RS66721B1/sr unknown
- 2020-12-08 EP EP24205932.7A patent/EP4483882A3/en active Pending
- 2020-12-08 CR CR20220251A patent/CR20220251A/es unknown
- 2020-12-08 UA UAA202202163A patent/UA128299C2/uk unknown
- 2020-12-08 PT PT208173773T patent/PT4073065T/pt unknown
- 2020-12-08 IL IL292161A patent/IL292161B2/en unknown
- 2020-12-08 SI SI202030605T patent/SI4073065T1/sl unknown
- 2020-12-08 CN CN202080084994.3A patent/CN114787156B/zh active Active
- 2020-12-08 FI FIEP20817377.3T patent/FI4073065T3/fi active
- 2020-12-08 CN CN202410878222.7A patent/CN118791472A/zh active Pending
- 2020-12-08 EP EP20817377.3A patent/EP4073065B1/en active Active
- 2020-12-08 HU HUE20817377A patent/HUE071148T2/hu unknown
- 2020-12-08 KR KR1020227023074A patent/KR102836833B1/ko active Active
- 2020-12-08 MA MA58087A patent/MA58087B1/fr unknown
- 2020-12-08 ES ES20817377T patent/ES3023264T3/es active Active
- 2020-12-08 IL IL316473A patent/IL316473A/en unknown
- 2020-12-09 AR ARP200103417A patent/AR122351A1/es unknown
- 2020-12-09 TW TW109143500A patent/TWI877268B/zh active
- 2020-12-09 TW TW113139852A patent/TWI908405B/zh active
-
2021
- 2021-12-14 JP JP2021202780A patent/JP7802514B2/ja active Active
-
2022
- 2022-04-26 ZA ZA2022/04675A patent/ZA202204675B/en unknown
- 2022-06-08 US US17/835,245 patent/US12116349B2/en active Active
- 2022-06-09 CL CL2022001529A patent/CL2022001529A1/es unknown
- 2022-06-22 ZA ZA2022/06923A patent/ZA202206923B/en unknown
- 2022-06-28 CO CONC2022/0008968A patent/CO2022008968A2/es unknown
-
2023
- 2023-11-30 US US18/525,536 patent/US20240174621A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4073065T3 (da) | Hidtil ukendte methylquinazolinonderivativer | |
| PT3958977T (pt) | Derivados de camptotecina | |
| DK4067344T3 (da) | Cycloalkylurinstofderivat | |
| LT3830085T (lt) | Deuterinti lanifibranoro dariniai | |
| DK3810587T3 (da) | Substituerede alkoxypyridinylindolsulfonamider | |
| EP4013751C0 (en) | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | |
| PL3897842T3 (pl) | Pochodne bicykliczne | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| EP4077334C0 (en) | FUROINDAZOLE DERIVATIVES | |
| EP4021904C0 (en) | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | |
| EP3930851A4 (en) | COMBINATION THERAPIES | |
| EP3919491C0 (en) | AKT INHIBITOR | |
| EP3967649C0 (en) | LIPID NANOPARTICLE | |
| PL4301748T3 (pl) | Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu | |
| EP3884940A4 (en) | Novel imidazole derivative | |
| DK3823970T3 (da) | Yderligere substituerede triazoloquinoxalinderivater | |
| EP3742771C0 (en) | M2M SM-SR TO SM-DP NOTIFICATION | |
| PL3898637T3 (pl) | Pochodne rapamycyny | |
| DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
| EP3885347A4 (en) | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | |
| DK3796975T3 (da) | Sulfonylaminobenzamidderivater | |
| EP3912517C0 (en) | FRAME | |
| EP3957391C0 (en) | AGITATOR | |
| DK4396183T3 (da) | Substituerede s-alaninatderivater | |
| DK3894410T3 (da) | Substituerede xanthinderivater |